A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Mas, Emilie; Barden, Anne; Burke, Valerie; Beilin, Lawrence J.; Watts, Gerald F.; Huang, Rae‐Chi; Puddey, Ian B.; Irish, Ashley; Mori, Trevor A.

doi:10.1016/j.clnu.2015.04.004

Cited by 57 publications

(45 citation statements)

References 37 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, recent randomized controlled human trials indicate that omega-3 intake elevated 17-HDHA and RvD1 plasma levels in patients with chronic kidney diseases (28) as well as in chronic knee effusions and plasma in arthritis patients (29). Thus, these and our present findings may have implications for human chronic inflammatory diseases.…”

Section: Discussionmentioning

confidence: 99%

Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation

Arnardottir

Dalli

Norling

et al. 2016

The Journal of Immunology

117

View full text Add to dashboard Cite

Uncontrolled inflammation is a unifying component of many chronic inflammatory diseases, such as arthritis. Resolvins (Rv) are a new family from the endogenous specialized pro-resolving lipid mediators (SPM) that actively stimulate resolution of inflammation. Herein, using lipid mediator (LM) metabololipidomics with murine joints we found a temporal regulation of endogenous SPM during self-resolving inflammatory arthritis. The SPMs present in self-resolving arthritic joints include the D-series resolvins, e.g. Resolvin (Rv) D1, RvD2, RvD3 and RvD4. Of note, RvD3 levels were reduced in inflamed joints from mice with delayed-resolving arthritis when compared to self-resolving inflammatory arthritis. RvD3 was also reduced in serum from rheumatoid arthritis (RA) patients compared to healthy controls. RvD3 administration reduced joint leukocytes as well as paw joint eicosanoids, clinical scores and edema. Together, these findings provide evidence for dysregulated endogenous RvD3 levels in inflamed paw joints and its potent actions in reducing murine arthritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation

Arnardottir

Dalli

Norling

et al. 2016

The Journal of Immunology

117

View full text Add to dashboard Cite

show abstract

“…Previous studies examining the presence of SPM in adults have looked at subsets with specific diseases, including asthma, Alzheimer’s disease, multiple sclerosis, chronic kidney disease, peripheral artery disease, and rheumatoid arthritis (Serhan, 2014; Grenon et al, 2015; Mas et al, 2016) as well as in unselected adults (Psychogios et al, 2011). In the reproductive sphere, maternal omega-3 fatty acid supplementation with 3.7 g DHA plus EPA was shown to increase resolvin and protectin precursors in human placental tissues; likewise, a high n-3 PUFA diet has been shown to increase SPM precursors in rat placentas (Jones et al, 2013; Keelan et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study

et al. 2016

View full text Add to dashboard Cite

The omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are precursors to immune regulatory and specialized pro-resolving mediators (SPM) of inflammation termed resolvins, maresins, and protectins. Evidence for lipid mediator formation in vivo can be gained through evaluation of their 5-lipoxygenase (LOX) and 15-LOX metabolic pathway precursors and downstream metabolites. We performed a secondary blood sample analysis from 60 participants in the Mothers, Omega-3, and Mental Health study to determine whether SPM and SPM precursors are augmented by dietary EPA- and DHA-rich fish oil supplementation compared to soy oil placebo. We also aimed to study whether SPM and their precursors differ in early and late pregnancy or between maternal and umbilical cord blood. We found that compared to placebo supplementation, EPA- and DHA-rich fish oil supplementation increased SPM precursor 17-hydroxy docosahexaenoic acid (17-HDHA) concentrations in maternal and umbilical cord blood (P = 0.02). We found that the D-series resolvin pathway marker 17-HDHA increased significantly between enrollment and late pregnancy (P = 0.049). Levels of both 14-HDHA, a maresin pathway marker, and 17-HDHA were significantly greater in umbilical cord blood than in maternal blood (P < 0.001, both).

show abstract

“…34 Donadio where consumption of fish and seafoods is also relatively high. 7,12,38,39 The cumulative incidence of adverse events during follow-up did not differ between the groups. Also, explorative studies investigating effects of marine n-3 FA consumption on mechanisms involved in development of renal graft fibrosis would be of interest.…”

mentioning

confidence: 83%

Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial

Eide

Reinholt

Jenssen

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

Marine n-3 fatty acids (FAs) may exert beneficial effects on inflammation, fibrosis, and endothelial function, which could preserve renal graft function. In this randomized controlled trial, 132 Norwegian renal transplant recipients received either 2.6 g of marine n-3 FAs or olive oil (control) daily for 44 weeks, in addition to standard care. Thirty patients did not complete the trial. The primary endpoint was change (Δ) in measured glomerular filtration rate (mGFR) during follow-up. We found no significant difference in Δ mGFR between the marine n-3 FA group and controls (6.7 vs 3.8 mL/min per 1.73 m , P = .15). Significant beneficial effects from marine n-3 FA supplementation were, however, seen in secondary endpoints plasma triglycerides, plasma high-sensitivity C-reactive protein, and brachial artery flow-mediated dilation. In the per-protocol population, the renal graft indices percent interstitial fibrosis and Chronic Allograft Damage Index also were significantly lower in the marine n-3 FA group. The cumulative incidence of adverse events did not differ between the marine n-3 FA group (n = 218) and controls (n = 240). In conclusion, marine FA supplementation did not improve renal function compared with controls, but was safe, lowered plasma triglyceride and high-sensitivity C-reactive protein levels, and improved endothelial function (Clinical.Trials.gov identifier NCT01744067).

show abstract

A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease

Abstract: SPMs are increased after 8 weeks n-3 fatty acid supplementation in patients with CKD. This may have important implications for limiting ongoing low grade inflammation in CKD.

Cited by 57 publications

References 37 publications

Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation

Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation

Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study

Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial

Contact Info

Product

Resources

About